Journal
WORLD JOURNAL OF GASTROENTEROLOGY
Volume 13, Issue 6, Pages 830-836Publisher
BAISHIDENG PUBLISHING GROUP INC
DOI: 10.3748/wjg.v13.i6.830
Keywords
hepatitis B virus; antiviral drugs; drug evaluation; immunomodulatory agents; gene therapy
Categories
Ask authors/readers for more resources
Currently approved treatments for hepatitis B virus (HBV) infection include the immunomodulatory agent, IFN-alpha, and nucleos(t)ide analogues. Their efficacy is limited by their side effects, as well as the induction of viral mutations that render them less potent. It is thus necessary to develop drugs that target additional viral antigens. Chemicals and biomaterials by unique methods of preventing HBV replication are currently being developed, including novel nucleosides and newly synthesized compounds such as capsid assembling and mRNA transcription inhibitors. Molecular therapies that target different stages of the HBV life cycle will aid current methods to manage chronic hepatitis B (CHB) infection. The use of immunomodulators and gene therapy are also under consideration. This report summarizes the most recent treatment possibilities for CHB infection. Emerging therapies and their potential mechanisms, efficacy, and pitfalls are discussed. (C) 2007 The WJG Press. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available